Monday, February 4, 2013
The recent change in policy by Dupont with regard to the Oncomouse patent opens the door to academic-pharma collaboration. It may also be possible to streamline development of novel drug testing by creating a non-profit company or organization for this specific purpose. Rhabdomyosarcoma, Inc? Would members of the community have interest in such an endeavor?